Diabetes Research and Clinical Practice
Volume 57, Issue 1 , Pages 1-10 , July 2002

Probucol preserves pancreatic β-cell function through reduction of oxidative stress in type 2 diabetes

Received 15 October 2001 ,Revised 17 December 2001 ,Accepted 27 December 2001.

References 

  1. Porte D. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes. 1991;40:166–180
  2. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15:318–368
  3. Yki-Jarvinen H. Glucose toxicity. Endocr. Rev. 1992;13:415–431
  4. Zangen DH, Bonner-Weir S, Lee CH, et al.  Reduced insulin, GLUT2, and IDX-1 in beta-cells after partial pancreatectomy. Diabetes. 1997;46:258–264
  5. Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF. Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. J. Clin. Invest. 1992;90:320–325
  6. Olson LK, Redmon JB, Towle HC, Robertson RP. Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. J. Clin. Invest. 1993;92:514–519
  7. Sharma A, Olson LK, Robertson RP, Stein R. The reduction of insulin gene transcription in HIT-T15 beta cells chronically exposed to high glucose concentration is associated with the loss of RIPE3b1 and STF-1 transcription factor expression. Mol. Endocrinol. 1995;9:1127–1134
  8. Poitout V, Olson LK, Robertson RP. Chronic exposure of betaTC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. J. Clin. Invest. 1996;97:1041–1046
  9. Moran A, Zhang HJ, Olson LK, Harmon JS, Poitout V, Robertson RP. Differentiation of glucose toxicity from beta cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. J. Clin. Invest. 1997;99:534–539
  10. Sakurai T, Tsuchiya S. Superoxide production from nonenzymatically glycated protein. FEBS Lett. 1988;236:406–410
  11. Hunt JV, Smith CC, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes. 1990;39:1420–1424
  12. Matsuoka T, Kajimoto Y, Watada H, et al.  Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J. Clin. Invest. 1997;99:144–150
  13. Nishikawa T, Edelstein D, Du XL, et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–790
  14. Tajiri Y, Moller C, Grill V. Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function. Endocrinology. 1997;138:273–280
  15. Ihara Y, Toyokuni S, Uchida K, et al.  Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes. 1999;48:927–932
  16. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic. Biol. Med. 1996;20:463–466
  17. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc. Natl. Acad. Sci. USA. 1999;96:10 857–10 862
  18. Kaneto H, Kajimoto Y, Miyagawa J, et al.  Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes. 1999;48:2398–2406
  19. Tardif JC, Cote G, Lesperance J, et al.  Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and probucol study group. N. Engl. J. Med. 1997;337:365–372
  20. Keaney JF, Xu A, Cunningham D, Jackson T, Frei B, Vita JA. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J. Clin. Invest. 1995;95:2520–2529
  21. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 1995;332:488–493
  22. Tasaka Y, Nakaya H, Omori Y. Effects of aminoguanidine on glucagon and insulin release from rat pancreatic islet. Endocr. J. 1996;43:725–730
  23. Nishio Y, Kashiwagi A, Taki H, et al.  Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes. 1998;47:1318–1325
  24. Takahara N, Kashiwagi A, Nishio Y, et al.  Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells. Diabetologia. 1997;40:662–670
  25. Fukuda M, Ikegami H, Kawaguchi Y, Sano T, Ogihara T. Antioxidant, probucol, can inhibit the generation of hydrogen peroxide in islet cells induced by macrophages and prevent islet cell destruction in NOD mice. Biochem. Biophys. Res. Commun. 1995;209:953–958
  26. Matsushita M, Yoshino G, Iwai M, et al.  Protective effect of probucol on alloxan diabetes in rats. Diabetes Res. Clin. Pract. 1989;7:313–316
  27. Bruning JC, Michael MD, Winnay JN, et al.  A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell. 1998;2:559–569
  28. Wojtaszewski JFP, Higaki Y, Hirshman MF, et al.  Exercise modulates postreceptor insulin signaling and glucose transport in muscle-specific insulin receptor knockout mice. J. Clin. Invest. 1999;104:1257–1264
  29. Yoshino G, Matsushita M, Maeda E, et al.  Effect of probucol on triglyceride turnover in streptozotocin-diabetic rats. Atherosclerosis. 1991;88:69–75
  30. Sheetz MJ, Barnhart RL, Jackson RL, Robinson KM. MDL 29311, an analog of probucol, decreases triglycerides in rats by increasing hepatic clearance of very-low-density lipoprotein. Metabolism. 1994;43:233–240
  31. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur. J. Clin. Pharmacol. 1983;25:57–63
  32. Kahn CR, Weir GC. In:  Mahe PS editors. Joslin's Diabetes Mellitus. 13th ed.. Philadelphia, PA: Lea & Febiger; 1994;p. 97–115
  33. Shimabukuro M, Ohneda M, Lee Y, Unger RH. Role of nitric oxide in obesity-induced beta cell disease. J. Clin. Invest. 1997;100:290–295

PII: S0168-8227(02)00005-0

Diabetes Research and Clinical Practice
Volume 57, Issue 1 , Pages 1-10 , July 2002

Article Tools

* Image Usage & Resolution